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Background
T cells recognize cancer cells via human leukocyte antigen
(HLA)/peptide complexes, and class I HLA-restricted
tumor infiltrating T lymphocytes correspond to favorable
prognosis in several cancers, including ovarian cancer–the
most deadly gynecologic disease [1]. The accurate identifi-
cation of tumor-specific HLA/peptide complexes is pivotal
to their exploitation as targets in immunotherapies such as
peptide vaccination, transgenic T cell therapy, or antibody
tumor targeting. Here, a high-throughput peptide analysis
method was used to directly sequence the HLA-A*02:01
peptidome of ovarian cancer cells and to identify HLA/
peptide complexes distinct to tumor cells.
Methods
A secreted form of HLA-A*02:01 was stably transfected
into the SKOV-3, A2780, and OV-90 human ovarian can-
cer cell lines, as well as the immortalized normal ovarian
epithelial cell line FHIOSE. Yields of HLA in excess of 10
mg were harvested from bioreactors of each cell line and
purified from supernatants by affinity chromatography.
The bound peptides were purified from the HLA and
fractionated by two dimensions of high-pressure liquid
chromatography followed by mass spectrometry for
peptide sequencing.
Results
For each cell line, approximately 14,000 non-redundant
peptides were identified at a 1% false discovery rate against
a decoy database. A clear overarching HLA-A*02:01 motif
was observed. Upon comparison, >100 peptides appeared
absent from the line derived from normal ovarian epithe-
lium but were consistent to all three ovarian cancer lines.
In addition, 41 peptides derived from the tumor antigen
human epidermal growth factor receptor 2 (HER2) were
sequenced from the HER2 overexpressor SKOV3. Eight of
these ligands confirm predicted peptides from the litera-
ture that have shown immunogenicity, including the
highly targeted E75.
Conclusion
Class I HLA gathered from tumor cells provides for
the direct characterization of the cancerous peptidome.
Ovarian cancers are highly heterogeneous, but this high-
throughput peptide sequencing method is able to detect
and highlight the consistencies in cancer-associated HLA
peptide presentation–at least among three disparate cases.
It has also provided the first direct sequencing evidence of
HER2 peptides, confirming eight predictions and revealing
33 novel tumor ligands from this highly targeted cancer
protein. In characterizing and comparing cancerous and
non-cancerous peptidomes, this study has highlighted
multiple candidate peptides for tumor-specific targeting in
ovarian cancer immunotherapy.
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